Showing 1371-1380 of 1697 results for "".
- Muscular Dystrophy Association Launches Initiative to Support the Development of Treatments for Ultra-Rare Neuromuscular Diseaseshttps://practicalneurology.com/news/muscular-dystrophy-association-launches-initiative-to-support-the-development-of-treatments-for-ultra-rare-neuromuscular-diseases/2470571/The Muscular Dystrophy Association (MDA) announced the launch of the MDA Kickstart Program, an initiative to advance the development of treatments for ultra-rare neuromuscular diseases. The first project under the MDA Kickstart Program will focus on the development of a gene therapy for a rare fo
- Leqembi Treatment Associated with Sustained Reduction in Cognitive Decline According to 3-Year OLE Resultshttps://practicalneurology.com/news/leqembi-treatment-associated-with-sustained-reduction-in-cognitive-decline-according-to-3-year-ole-results/2470545/New 3-year open-label extension (OLE) results from the Clarity AD clinical trial (NCT03887455) presented at the 2024 meeting of the Alzheimer’s Association International Conference (AAIC) showed sustained reductions in cognitive decline in participants with early Alzheimer disease (AD) trea
- FDA Approves Once-Daily Austedo XR for Tardive Dyskinesia and Chorea Associated with Huntington Diseasehttps://practicalneurology.com/news/fda-approves-once-daily-austedo-xr-for-tardive-dyskinesia-and-chorea-associated-with-huntington-disease/2470487/The Food and Drug Administration (FDA) has approved Austedo XR (deutetrabenazine; Teva Neuroscience, Kansas City, MO) extended-release tablets, a new once-daily formulation of Austedo for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington disease (HD) in adults. Austed
- Significant Association Between COVID-19 Infection and Cerebral Microbleeds Found in New Studyhttps://practicalneurology.com/news/significant-association-between-covid-19-infection-and-cerebral-microbleeds-found-in-new-study/2470465/According to study results published in Brain Communications, COVID-19 infection was associated with a significantly greater likelihood of cerebral microbleeds (CMBs) on medically indicated brain MRI. Incidental findings of CMBs have been discovered on brain MRI in COVID-19 cohorts
- FDA Approves Ingrezza Sprinkle Formulation for Tardive Dyskinesia or Chorea Associated with Huntington Diseasehttps://practicalneurology.com/news/fda-approves-ingrezza-sprinkle-formulation-for-tardive-dyskinesia-or-chorea-associated-with-huntington-disease/2470463/The Food and Drug Administration (FDA) has approved a new sprinkle formulation of Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) for patients with tardive dyskinesia (TD) or chorea associated with Huntington disease (HD). The oral granule capsules (available in 40 mg, 60 mg, and 80
- Treatment of Focal Epilepsy with Cenobamate Associated with Lower Inpatient Days and ER Visits Compared with 7 Leading Anti-Seizure Medicationshttps://practicalneurology.com/news/treatment-of-focal-epilepsy-with-cenobamate-associated-with-lower-inpatient-days-and-er-visits-compared-with-7-leading-anti-seizure-medications/2470448/The addition of cenobamate to the treatment regimens of people with focal epilepsy was associated with lower rates of inpatient days and emergency room (ER) visits compared with the addition of 7 other leading anti-seizure medications (ASMs). This finding, which was presented at the American Acad
- New Partnership Between myTomorrows and the ALS Association Aims to Expand Clinical Trial Participationhttps://practicalneurology.com/news/new-partnership-between-mytomorrows-and-the-als-association-aims-to-expand-clinical-trial-participation/2470426/The global health technology company myTomorrows has announced a new partnership with the ALS Association, a US nonprofit organization working to combat amyotrophic lateral sclerosis (ALS) through research, governmental partnerships, and coordinating care and assistance for people with ALS. This
- Large-Scale Study in The Lancet Neurology Documents Demographic, Clinical, and Biomarker Features Associated with Posterior Cortical Atrophyhttps://practicalneurology.com/news/large-scale-study-in-the-lancet-neurology-documents-demographic-clinical-features-and-biomarkers-associated-with-posterior-cortical-atrophy/2470389/Findings from a large-scaled research study published in The Lancet Neurology, provide new insight into the demographic characteristics of posterior cortical atrophy (PCA), which is a rare syndrome associated with the underlying neuropathologic features of Alzheimer disease (AD). Accordi
- Botulinum Toxin A Treatment Associated with Improvements in Essential and Isolated Head Tremor According to Results from RCThttps://practicalneurology.com/news/botulinum-toxin-a-treatment-associated-with-improvements-in-essential-and-isolated-head-tremor-according-to-results-from-rct/2470365/Injection of botulinum toxin A into the splenius capitis muscle was associated with reductions in the severity of essential and isolated head tremor, according to results from a randomized clinical trial published in The New England Journal of Medicine. Secondary outcome measures from th
- Lumryz Treatment Associated with Significant Improvements in Mean Sleep Latency According to REST-ON Studyhttps://practicalneurology.com/news/lumryz-treatment-associated-with-significant-improvements-in-mean-sleep-latency-according-to-rest-on-study/2470322/Use of once-nightly (ON) Lumryz (sodium oxybate; Avadel Pharmaceuticals, Dublin, Ireland) was associated with clinically significant improvements in mean sleep latency compared with placebo according to a presentation at the World Sleep 2023 Congress. The results were from a post hoc analysis of